BioNTech to purchase FDA priority review voucher from Scholar Rock for $205 million
BioNTech announced an agreement to acquire an FDA Priority Review Voucher from Scholar Rock for a cash consideration of $205 million. The voucher will allow BioNTech to obtain priority review for a future oncology filing in its late‑stage pipeline. The transaction is subject to customary closing conditions, including Hart‑Scott‑Rodino antitrust clearance.
Why it matters
The $205 million cash outlay represents a significant commitment that could accelerate the regulatory timeline for BioNTech’s oncology asset, potentially enhancing its market launch prospects. Completion of the deal depends on regulatory approval, so the transaction may not affect cash balances until closing.
Key facts
- 1BioNTech agreed to pay $205 million in cash to Scholar Rock for the FDA Priority Review Voucher. quantisnow.com
- 2The voucher grants priority review for a single future FDA application. quantisnow.com
- 3The transaction is pending Hart‑Scott‑Rodino antitrust clearance. quantisnow.com
- 4Scholar Rock is the seller of the voucher. tradingview.com
- 5The agreement was announced on November 10, 2026. tipranks.com
- 6BioNTech intends to use the voucher to expedite a filing for an asset in its late‑stage oncology pipeline. seekingalpha.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.